EYLEA Age-Related Macular Degeneration (AMD) post-marketing surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.
A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.
- Patients who received EYLEA for AMD
- Patients who have already received EYLEA
Many Locations, Japan
StatusActive, not recruiting
E-mail: [email protected]
Phone: (+) 1-888-8422937
Special drug use investigation of EYLEA for AMD